NASDAQ · XENE
Healthcare · Biotechnology
$37.41
Up+$0.56 (+1.50%)
Updated Nov 2, 2026, 3:45 PM
SID Score
4.2/10
Composite research score
Smart Money
58/100
Neutral
Price performance · XENE
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
XENE closed at $37.41 after 20 trading sessions, down 0.43% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $37.54 | $38.12 | $36.84 | $37.41 | 1.12M |
| Oct 29, 2026 | $37.27 | $37.685 | $36.49 | $37.54 | 1.55M |
| Oct 28, 2026 | $35.71 | $36.62 | $35.37 | $36.34 | 2.13M |
| Oct 27, 2026 | $35.61 | $36.21 | $35.3375 | $36.01 | 1.09M |
| Oct 26, 2026 | $35.34 | $35.82 | $35.09 | $35.77 | 726.71K |
| Oct 23, 2026 | $36.62 | $36.62 | $35.23 | $35.34 | 636.6K |
| Oct 22, 2026 | $35.92 | $36.90 | $35.695 | $36.50 | 1.38M |
| Oct 21, 2026 | $36.55 | $37.00 | $35.89 | $35.95 | 1.08M |
| Oct 20, 2026 | $35.14 | $36.645 | $35.10 | $36.27 | 990.76K |
| Oct 19, 2026 | $33.89 | $35.14 | $33.72 | $35.08 | 1.21M |
| Oct 16, 2026 | $34.34 | $34.375 | $33.38 | $33.49 | 1.08M |
| Oct 15, 2026 | $34.11 | $34.99 | $33.99 | $34.33 | 1.62M |
| Oct 14, 2026 | $34.12 | $34.84 | $33.52 | $33.90 | 1.79M |
| Oct 13, 2026 | $35.65 | $35.9024 | $34.38 | $34.42 | 1.11M |
| Oct 12, 2026 | $36.45 | $36.54 | $35.57 | $35.81 | 764.61K |
| Oct 9, 2026 | $36.05 | $36.70 | $35.98 | $36.44 | 1.24M |
| Oct 8, 2026 | $36.13 | $36.41 | $35.06 | $36.16 | 2.27M |
| Oct 7, 2026 | $36.19 | $36.56 | $35.78 | $36.41 | 1.97M |
| Oct 6, 2026 | $37.78 | $37.79 | $35.75 | $36.57 | 2.79M |
| Oct 5, 2026 | $38.02 | $38.225 | $37.00 | $37.57 | 1.7M |
The latest Smart Investors Daily articles mentioning XENE.
Company
Market Activity
Research & News
XENE research
Company profile and research snapshot.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 18, 2026 | Wedbush | Outperform | — |
| Sep 18, 2026 | RBC Capital | Outperform | — |
| Sep 18, 2026 | Wells Fargo | Overweight | — |
| Sep 18, 2026 | Deutsche Bank | Hold | — |
| Sep 18, 2026 | Baird | Outperform | — |
No generated briefing is available yet.
Benzinga · Oct 12, 2026
Xenon Pharmaceuticals (NASDAQ:XENE) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by
Yahoo · Oct 9, 2026
Xenon Pharmaceuticals (XENE) has drawn fresh attention after a sharp pullback, with the stock down about 38% over the past month and roughly 47% over the past 3 months. The recent slide comes after a softer year overall for Xenon Pharmaceuticals, with the share price return down 18.1% year to date and shorter term momentum fading, despite a modest 0.8% gain in the latest session. Scan beyond Xenon Pharmaceuticals and see how it stacks up against a hand picked list of solid balance sheet and...
Yahoo · Oct 9, 2026
Xenon Pharmaceuticals has seen a sharp reset in sentiment recently, with the share price falling 39.3% over the past month. After that kind of slide, the immediate question for investors is whether the current market value still lines up with what the company’s balance sheet and book value suggest. The stock is down 39.3% over the past 30 days. This puts fresh focus on whether the recent drop has meaningfully altered how its book value compares with the share price. The business leans...
Yahoo · Oct 7, 2026
Insider activity can provide investors with useful clues about how corporate leaders view their own companies. Executives and directors have firsthand knowledge of their businesses, making their disclosed stock transactions worth following. Insider sales can happen for many reasons, including tax planning, portfolio diversification, or personal liquidity needs. Insider purchases, however, can carry more weight. When executives or directors commit significant amounts of their own money to company
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning XENE.
